Shanton to Present Topline Data from Phase 2b Study with SAP-001 in Refractory Gout Patients at EULAR 2025 Congress

SAP-001 is Shanton’s lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., May 19, 2025 /PRNewswire/ — Shanton Pharma, a clinical-stage biotech company developing a novel treatment for gout, today announced that it will…